PMID- 7507709
OWN - NLM
STAT- MEDLINE
DCOM- 19940307
LR  - 20191031
IS  - 1067-5582 (Print)
IS  - 1067-5582 (Linking)
VI  - 14
IP  - 3
DP  - 1993 Oct
TI  - Differential regulation of human leukocyte antigen class I genes by interferon in 
      vivo and in vitro.
PG  - 169-74
AB  - Modulation of human leukocyte antigen (HLA) class I antigens on peripheral blood 
      lymphocytes, monocytes, and hematopoietic precursors during interferon-alpha 
      (IFN-alpha) therapy was investigated in 18 patients with myeloproliferative 
      syndrome. After 1 month of IFN-alpha therapy, an increased number of monocytes 
      and hematopoietic precursor cells but not of lymphocytes expressed HLA-DQ 
      antigens. In addition, a strong induction of HLA class I antigens was found on 
      both hematopoietic progenitors and normal peripheral blood mononuclear cells. By 
      daily injections of IFN in the first month of therapy, stimulation continuously 
      increased, suggesting a major effect of IFN alpha on hematopoietic progenitors 
      with sustained enhanced expression of HLA class I antigens during differentiation 
      of myelomonocytic cells. HLA class I antigen expression was consistently 
      augmented by IFN alpha in all patients irrespective of their hematologic 
      response. Differential in vivo regulation of HLA class I antigens by IFN was 
      confirmed by comparison of HLA-A2 with HLA-B antigen expression. In vitro 
      expression of the HLA-B7 and -Bw64 genes had been shown earlier to be 
      significantly more inducible by IFN than the genes coding for several other HLA 
      class I antigens after transfection into mouse L cells. Modification of the 5' 
      ends of the HLA-B7 and HLA-B27 genes before transfection in mouse L cells showed 
      the presence of enhancer sequences responding to IFN treatment in the 5' 
      untranslated region of the HLA-B7 but not of the HLA-B27 gene and suggested the 
      presence of independently acting regulatory mechanisms independent of these 
      enhancers.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Schmidt, H
AU  - Schmidt H
AD  - Med. Universitatsklinik u. Poliklinik, Tubingen, Germany.
FAU - Kellermann-Kegreiss, E
AU  - Kellermann-Kegreiss E
FAU - Steiert, I
AU  - Steiert I
FAU - Walz, J
AU  - Walz J
FAU - Zinser, R
AU  - Zinser R
FAU - Muller, C A
AU  - Muller CA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Immunother Emphasis Tumor Immunol
JT  - Journal of immunotherapy with emphasis on tumor immunology : official journal of 
      the Society for Biological Therapy
JID - 9418950
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, CD34)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Interferon-alpha)
SB  - IM
MH  - Animals
MH  - Antigens, CD/biosynthesis
MH  - Antigens, CD34
MH  - Cell Line
MH  - Female
MH  - Gene Expression Regulation/*drug effects
MH  - Genes, MHC Class I/*drug effects
MH  - Histocompatibility Antigens Class I/biosynthesis
MH  - Humans
MH  - Interferon-alpha/*therapeutic use
MH  - Male
MH  - Mice
MH  - Myeloproliferative Disorders/genetics/*therapy
EDAT- 1993/10/01 00:00
MHDA- 1993/10/01 00:01
CRDT- 1993/10/01 00:00
PHST- 1993/10/01 00:00 [pubmed]
PHST- 1993/10/01 00:01 [medline]
PHST- 1993/10/01 00:00 [entrez]
AID - 10.1097/00002371-199310000-00002 [doi]
PST - ppublish
SO  - J Immunother Emphasis Tumor Immunol. 1993 Oct;14(3):169-74. doi: 
      10.1097/00002371-199310000-00002.